Biogenic Amines & Condiment Safety Patents: Leaders & Gaps 2026
- 28.7% concentration. The top five assignees hold 107 of 373 records in scope — a tight cluster at the top with a long tail of single-filing entrants below it.
- Medicinal framing dominates. 62.2% of records sit in A61K (medicinal preparations) versus 16.4% in A23L (foods), showing most claims are written as therapeutic or enzyme interventions rather than food-process protections.
- Filing cooled after 2023. Volume peaked at 31 records in 2023; the complete-year comparison shows a 39% pullback from 2021 to 2024, though 2025-26 figures are still filling in under publication lag.
Filing growth compares 2021 (28 records) with 2024 (17) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 373 records in scope (CR5), not by the ranked leaders only.
What this patent landscape covers
Biogenic amines — histamine, tyramine and related compounds formed by amine oxidase activity during fermentation — sit at the intersection of food safety regulation and enzyme science. This landscape tracks 373 patent records published between 2015 and mid-2026 that combine biogenic amine or fermented food safety language with a specific control mechanism: histamine formation, amine oxidase activity, ethyl carbamate, mycotoxin risk, process intervention or limit specification. The scope deliberately pairs a safety concern with a named technical lever, which is why so many records land in pharmaceutical-facing IPC classes alongside food-process ones.
The dataset spans assignees ranging from university research foundations to pharmaceutical developers and food-processing equipment makers, filed across six major receiving offices. Family counts, not raw document counts, anchor the assignee ranking below, which reduces the distortion that comes from continuation filings and multi-jurisdiction duplicates.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 373-record corpus: how filing activity moved year over year, and how those records distribute across the IPC subclasses that define the technical approach.
A decade of uneven filing, peaking in 2023
Annual volume rose from 7 records in 2017 to a peak of 31 in 2023, then eased to 17 by 2024 — a complete-year decline of 39% from the 2021 level of 28. Records from 2025 onward are undercounted because publication typically lags filing by roughly 18 months, so the most recent bars will fill in over time rather than representing a confirmed drop.
Medicinal and therapeutic classes outweigh food-process ones
A61K (medicinal preparations) covers 62.2% of the 373 records and A61P (therapeutic activity) covers 39.1%, both well ahead of A23L (foods and non-alcoholic beverages) at 16.4%. C12N (microorganisms and genetic engineering) at 28.2% and C12Q (enzyme/DNA measurement) at 12.9% point to a corpus weighted toward biological mechanism and detection rather than food-manufacturing process claims. Because records can carry multiple IPC classes, these shares add up to well over 100% and should be read individually against the 373-record base, not summed.
Shares are the percentage of the 373 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Biogenic Amines and Condiment Safety with Eureka
This page is one run against one query. Ask Eureka your own question about biogenic amines and condiment safety and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
Method To Reduce Biogenic Amine Content in Food (US20130084358A1, Novozymes A/S)
This invention relates to a method of reducing biogenic amine content in a beverage by contacting the beverage and/or beverage intermediate with an enzyme having transglutaminase activity.Filed by Novozymes A/S, this record frames the safety problem as an enzyme-treatment step applied directly to a beverage or beverage intermediate, rather than as a downstream detection or therapeutic claim.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2018204764A1 | Identification and targeted modulation of gene signaling networks | 273 |
| 2 | US20190192691A1 | Regulated biocircuit systems | 218 |
| 3 | WO2017180587A2 | Regulated biocircuit systems | 171 |
| 4 | US20210254056A1 | Identification and targeted modulation of gene signaling networks | 144 |
| 5 | US20100063047A1 | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease | 125 |
| 6 | US20090264300A1 | Enzymatic encoding methods for efficient synthesis of large libraries | 122 |
| 7 | WO2007090852A1 | Amino pyrimidine compounds for the treatment of inflammatory disorders | 86 |
| 8 | US20130253029A1 | Novel bicyclic compounds | 56 |
| 9 | WO2007090854A1 | Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders | 55 |
| 10 | WO2001055301A2 | Nucleic acids, proteins, and antibodies | 48 |
Citation counts favour older filings that have had more time to accumulate citations within this searched corpus — read them as a signal of influence on later work, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three patterns stand out once family counts, IPC shares and the filing trend are read together.
A tight top tier, then a long tail
The top five assignees account for 107 of the 373 records in scope, and the top ten extend that to 171 records (45.8%). Below that tier the ranking thins quickly into single- and double-filing entrants, which is typical of a field still being explored by many small teams rather than settled by a handful of dominant players.
Claims skew pharmaceutical over food-process
Medicinal preparation and therapeutic-activity classes (A61K, A61P) outnumber food-specific classes (A23L) by a wide margin. That suggests the more crowded claim space is around treating or measuring amine-related biological effects, while food-manufacturing process claims — dosing, fermentation control, limit specification applied directly to a condiment line — are comparatively less contested.
Volume has pulled back from its 2023 peak
Filing rose steadily through the 2010s, peaked at 31 records in 2023, and had fallen to 17 by 2024 on a complete-year basis. Recent-year momentum by individual assignee is largely flat or at zero for the most recent tracked year, though this partly reflects publication lag rather than a confirmed stop in activity.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to biogenic amines and condiment safety, with the prior art for and against each one.
Who is filing, and where the openings sit
The ranked list mixes university research foundations, pharmaceutical developers and food-science institutes, with only ten documented co-assignee collaborations across the whole corpus.
One assignee well ahead of fifth place
The leading assignee holds 28 records against 17 at fifth place and 11 at tenth, a steep drop-off that marks this as a leader-plus-field structure rather than an even spread among a handful of comparable players.
Collaboration is rare and mostly institutional
Only ten co-assignee pairs appear in the whole dataset, and the strongest links are university-to-affiliate or university-to-researcher pairings rather than cross-company joint filings. Most assignees in this field are filing independently.
Recent-year filing has gone quiet across the leaders
Among the assignees tracked for recent-year momentum, most show zero records in the latest year, including one with a -100% year-on-year change. This is consistent with publication lag rather than a definitive stop, since the most recent filings have not fully surfaced yet.
| Assignee | Recent year | YoY |
|---|---|---|
| Oyster Point Pharma, Inc. | 1 | — |
| Yale University | 0 | — |
| Janssen Pharmaceutica NV | 0 | — |
| Iowa State University Research Foundation, Inc. | 0 | -100% |
| Tactogen Inc. | 0 | — |
| Otsuka America Pharmaceutical, Inc. | 0 | — |
| Jiangnan University | 0 | -100% |
| Nxera Pharma UK Limited | 0 | — |
Where to take this analysis
The patterns above point to specific next steps depending on whether the goal is freedom-to-operate, portfolio benchmarking or identifying where to file next.
Map claim scope on the top-cited records
The five most-cited records concentrate on gene-signaling networks, biocircuit systems and histamine-receptor inhibitors — read their independent claims before assuming a food-process route is blocked.
Explore claim charts in EurekaCheck the food-process white space directly
A23L and process-intervention claims are thinner than the medicinal classes; a targeted search inside Eureka can confirm whether a specific dosing or limit-specification approach is genuinely open.
Run a white space search in EurekaTrack the leader's recent filing behaviour
The top assignee's activity has slowed in the most recent tracked year alongside most peers; monitoring new publications as they clear the 18-month lag will show whether that holds.
Set up monitoring in EurekaCommon questions about this landscape
This landscape tracks 373 published patent records filed or published between 2015 and mid-2026 that combine biogenic amine or fermented food safety language with a named control mechanism such as histamine formation, amine oxidase activity or limit specification. Family counts are used for the assignee ranking rather than raw document counts, which avoids inflating the picture with continuation filings or duplicate national filings of the same invention. The true count for the most recent year or two is understated because publication typically lags filing by around 18 months.
The ranking returned for this search covers 100 companies and institutions, led by an assignee with 28 records, ahead of 17 at fifth place and 11 at tenth. The top five combined hold 107 of the 373 records (28.7%), and the top ten hold 171 (45.8%), so the field has a leader-plus-field structure rather than dominance by a single company. Below the top tier, filing thins quickly into a long tail of assignees with only one or two records each.
On a complete-year basis, filing grew from 7 records in 2017 to a peak of 31 in 2023, then fell to 17 by 2024 — a 39% decline over the 2021-to-2024 span. Figures for 2025 and 2026 appear lower still, but that reflects publication lag rather than a confirmed slowdown, since recently filed applications have not all cleared the publication pipeline. A fair read is that activity has cooled from its 2023 peak, with the true 2025-26 trajectory still to be confirmed.
The technology composition skews toward pharmaceutical and biological-mechanism classes: 62.2% of the 373 records fall in A61K (medicinal preparations) and 39.1% in A61P (therapeutic activity), compared with 16.4% in A23L (foods and non-alcoholic beverages). This means the more crowded claim territory concerns treating or measuring amine-related biological effects, while claims aimed directly at food-manufacturing process control are comparatively less contested. Because a single record can carry multiple IPC classes, these shares should be read individually rather than added together.
The IPC composition shows food-process classes such as A23L (16.4%) and C12Q enzyme/DNA measurement (12.9%) are far less dense than the medicinal classes, suggesting room for claims tied directly to condiment-line dosing, fermentation-stage process intervention, or amine-limit specification for shelf-stable products. Co-assignee collaboration is also rare — only ten pairs across the whole corpus — which points to limited cross-company joint development in this space so far. Any white-space conclusion should be confirmed with a targeted claim search before committing to a filing strategy.
Research Biogenic Amines and Condiment Safety in depth with Eureka
Go past this page: query the whole biogenic amines and condiment safety corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.